Jesse Jaynes

Dr. Jesse Jaynes

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 February 2020 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
JJJesse Jaynes
Jesse Jaynes
RSRushikesh Sable
Rushikesh Sable
MRMichael Ronzetti
Michael Ronzetti
WBWendy Bautista
Wendy Bautista
ZKZachary Knotts
Zachary Knotts
URUdo Rudloff
Udo Rudloff
Innate defense regulator RP-182 targets CD206 high M2-like macrophages in malignant and noncancerous diseases.

26 April 2023 in Cells
Verified
Journal Article
Open access
PDF file
AGAnghesom Ghebremedhin
Anghesom Ghebremedhin
ASAhmad Bin Salam
Ahmad Bin Salam
BABenjamin Adu-Addai
Benjamin Adu-Addai
SNSteve Noonan
Steve Noonan
RSRichard Stratton
Richard Stratton
CYClayton Yates
Clayton Yates
Activated M2-polarized macrophages are drivers of pulmonary fibrosis in several clinical scenarios, including Idiopathic Pulmonary Fibrosis (IPF). In this study, we investigated the effects of targeting the CD206 receptor in M2-like macrophages with a novel synthetic analogue of a naturally occurring Host Defense Peptide (HDP), RP-832c, to decrease profibrotic cytokines. RP-832c selectively binds to CD206 on M2-polarized bone marrow-derived macrophages (BMDM) in vitro, resulting in a time-dependent decrease in CD206 expression and a transient increase in M1-macrophage marker TNF-α. To elucidate the antifibrotic effects of RP-832c, we used a murine model of bleomycin (BLM)-induced early-stage pulmonary fibrosis. RP-832c significantly reduced fibrosis in a dose-dependent manner, and decreased CD206, TGF-β1, and α-SMA expression in mouse lungs. Similarly, in an established model of lung fibrosis, RP-832c significantly decreased lung fibrosis and significantly decreased inflammatory cytokines TNF-α, IL-6, IL-10, IFN-γ, CXCL1/2, and fibrosis markers TGF-β1 and MMP-13. In comparison with the FDA-approved drugs Nintedanib and Pirfenidone, RP-832c exhibited a similar reduction in fibrosis compared to Pirfenidone, and to a greater extent than Nintedanib, with no apparent toxicities observed. In summary, our findings showed that inhibiting the profibrotic alternatively activated M2-like macrophages using a novel peptide, RP-832c, could reduce BLM-induced pulmonary fibrosis in mice, warranting the therapeutic potential of this peptide for patients with pulmonary fibrosis.

13 January 2020 in Antibiotics
Verified
Journal Article
Open access
PDF file
KWKathryn Woodburn
Kathryn Woodburn
JJJesse Jaynes
Jesse Jaynes
LCLouis Clemens
Louis Clemens
Acne vulgaris, caused by the Gram-positive bacterium Cutibacterium acnes, is a prevalent dermatologic condition with substantial cutaneous and psychological morbidity. Mild acne is treated with topical antibiotics with more severe inflammatory forms requiring the prolonged use of oral antibiotics, resulting in antimicrobial resistance development. Innovative treatment alternatives, providing complete microbicidal eradication with minimal safety issues and limited susceptibility to microbial resistance, are fervently sought. Designed antimicrobial peptides (dAMPs) are engineered analogs of naturally occurring AMPs that possess a reduced likelihood of developing bacterial resistance. Seven novel dAMP sequences were screened for in vitro bactericidal effectiveness against antibiotic resistant C. acnes clinical isolates. Five peptides (RP444, RP551, RP554, RP556, and RP557) exhibited potent in vitro antibacterial activity. The Therapeutic Index, a measure of specificity for killing multidrug resistant C. acnes over mammalian cells, was determined using bioluminescent human keratinocytes. The Therapeutic Index was highest for the disulfide dAMP, RP556, with a value of 130. The lead dAMP candidate RP556, was further evaluated in a multidrug-resistant C. acnes intradermal murine infection model. A topical application of 5 mg/mL RP556 (0.5%) eliminated infection. If these preclinical results are translated clinically, dAMPs may become a viable topical monotherapy for the treatment of recalcitrant acne infections.

1 May 2018 in Plant Science
Verified
Journal Article
Closed access
KRKanniah Rajasekaran
Kanniah Rajasekaran
RSRonald J. Sayler
Ronald J. Sayler
CSChristine M. Sickler
Christine M. Sickler
RMRajtilak Majumdar
Rajtilak Majumdar
JJJesse Jaynes
Jesse Jaynes
JCJeffrey W. Cary
Jeffrey W. Cary

22 September 2020 in Journal of Fungi
Verified
Journal Article
Open access
PDF file
KWKathryn Woodburn
Kathryn Woodburn
JJJesse Jaynes
Jesse Jaynes
LCLouis Clemens
Louis Clemens
Cutaneous invasive fungal wound infections after life-threatening dismounted complex blast injury (DCBI) and natural disasters complicate clinical care. These wounds often require aggressive repeated surgical debridement, can result in amputations and hemipelvectomies and have a 38% mortality rate. Given the substantial morbidity associated with cutaneous fungal wound infections, patients at risk need immediate empiric treatment mandating the use of rapidly acting broad-spectrum antimicrobials, acting on both fungi and bacteria, that are also effective against biofilm and can be administered topically. Designed antimicrobial peptides (dAMPs) are engineered analogues of innate antimicrobial peptides which provide the first line of defense against invading pathogens. The antifungal and antibacterial effect and mammalian cytotoxicity of seven innovative dAMPs, created by iterative structural analog revisions and physicochemical and functional testing were investigated. The dAMPs possess broad-spectrum antifungal activity, in addition to being effective against Gram-negative and Gram-positive bacteria, which is crucial as many wounds are polymicrobial and require immediate empiric treatment. Three of the most potent dAMPs—RP504, RP556 and RP557—possess limited mammalian cytotoxicity following 8 h incubation. If these encouraging broad-spectrum antimicrobial and rapid acting results are translated clinically, these novel dAMPs may become a first line empiric topical treatment for traumatic wound injuries.

1 October 2023 in Plant Disease
Verified
Journal Article
Closed access
RSRebecca Sweany
Rebecca Sweany
Jeffrey CaryJeffrey Cary
Jeffrey Cary
JJJesse Jaynes
Jesse Jaynes
KRKanniah Rajasekaran
Kanniah Rajasekaran
Optimizing synthetic antimicrobial peptides for safe and enhanced activity against fungal and bacterial pathogens is useful for genetic engineering of plants for resistance to plant pathogens and their associated mycotoxins. Nine synthetic peptides modeled after lytic peptides tachyplesin 1, D4E1 from cecropin A and protegrin 1 were added to germinated spores of fungal species Aspergillus flavus, Rhizopus stolonifer, Fusarium oxysporum f. sp. vasinfectum, F. verticillioides, F. graminearum, Claviceps purpurea, Verticillium dahliae, Thielaviopsis basicola and bacterial cultures of Psuedomonas syringae p.v. tabaci and Xanthomonas campestris p.v. campestris at different doses and inhibitory dose response curves were modeled to assess antimicrobial activity. Peptides GV185 and GV187, modified from tachyplesin 1, had superior abilities to inhibit fungal and bacterial growth (50% inhibitory concentrations or IC50 ranging from 0.1 to 8.7 µM). Rhizopus stolonifer (IC50 = 8.1 µM), A. flavus (IC50 = 3.1 µM) and F. graminearum (IC50 = 2.2 µM) were less inhibited by GV185 and GV187 than all the remaining fungi (IC50 = 1.4 µM) and bacteria (IC50 = 0.1 µM). Of the remaining peptides, GV193, GV195 and GV196 (IC50 range 0.9 to 6.6 µM) inhibited fungal growth of A. flavus, F. verticillioides and F. graminearum less than GV185 and GV187 (IC50 range 0.8 to 3.9 µM), followed by GV197 (IC50 range 0.8 - 9.1 µM) whereas GV190 and GV192 inhibited poorly (IC50 range 28.2 to 36.6 µM and 15.5 to 19.4 µM, respectively) and GV198 stimulated growth. GV185 and GV187 had slightly weaker hydrophobic and cationic residues than other tachyplesin 1 modified peptides, but still had unexpectedly high lytic activity. Germinated fungal spores of R. stolonifer and F. graminearum exposed to these two peptides and D4E1 and AGM182 appeared wrinkled with perforations near potential cytoplasmic leakage, which provided evidence of plasma membrane and cell wall lysis. We conclude that peptides GV185 and GV187 are promising candidates for genetic engineering of crops for resistance to plant pathogenic bacteria and fungi including A. flavus and aflatoxin contamination.